Rigel Pharmaceuticals Inc
RIGL
NASDAQ
Biotechnology
$42.58
USD
+1.79 (+4.39%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $780.54M
Volume 224.0K
Revenue
$276.79M
TTM
+3.3%
YoY
Gross Margin
91%
TTM
-0.1%
YoY
Net Income
$321.91M
TTM
+229.1%
YoY
Operating Cash Flow
$79.39M
TTM
+20.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 101.7 | 69.5 | 69.8 | 58.8 | 78.7 |
YoY Growth | +176.0% | +25.6% | +21.2% | +10.3% | -22.6% |
Cost of Revenue | 4.5 | 4.8 | 6.0 | 4.6 | 8.5 |
Gross Profit | 97.2 | 64.7 | 63.8 | 54.2 | 70.2 |
Selling, General & Administrative | 29.3 | 28.9 | 30.0 | 30.7 | 32.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 36.1 | 36.3 | 40.7 | 42.3 | 46.6 |
Operating Income | 61.1 | 28.4 | 23.2 | 11.9 | 23.6 |
EBITDA | 61.7 | 29.0 | 23.8 | 12.5 | 24.4 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -1.1 | -0.8 | -0.5 | -0.2 | 0.0 |
Income Before Income Taxes | 60.0 | 27.6 | 22.7 | 11.7 | 23.6 |
Income Taxes | 0.4 | -0.3 | -245.4 | 3.0 | 6.3 |
Net Income | 59.6 | 27.9 | 268.1 | 8.7 | 17.3 |
Consolidated Net Income / Loss | 59.6 | 27.9 | 268.1 | 8.7 | 17.3 |
Net Income Attributable to Common Shareholders | 59.6 | 27.9 | 268.1 | 8.7 | 17.3 |
Basic EPS | $3.33 | $1.55 | $14.72 | $0.47 | $0.93 |
Diluted EPS | $3.28 | $1.46 | $13.49 | $0.44 | $0.88 |
Basic Shares Outstanding | 17.9M | 18.0M | 18.2M | 18.4M | 18.5M |
Diluted Shares Outstanding | 18.2M | 19.2M | 19.9M | 19.7M | 19.6M |